26 June 2020

Contents

Editorial

• HIV and COVID-19: issue 5 (26 June 2020) (HTB no 8)

Conference reports

• 23rd International AIDS Conference (AIDS 2020)

Antiretrovirals

• FDA approves dolutegravir formulations to treat infants and young children

COVID-19: HIV and COVID-19 coinfection

• Latest studies on HIV/COVID-19 coinfection

• HIV positive people in South Africa at increased risk of dying from COVID-19: first data from country with high prevalence of HIV and TB

• Update on Western Cape data: people with HIV have small increased risks from COVID-19

COVID-19: investigational drugs

• Dexamethasone significantly reduces mortality in subset of patients hospitalised with advanced COVID-19: UK RECOVERY study

• Modelling paper suggests hydroxychloroquine dosing was too low to be active against COVID-19 and that higher doses would risk toxicity

• FDA contraindication for remdesivir and hydroxychloroquine (HCQ): immediate impact on current HCQ research

• UK RECOVERY study stops hydroxychloroquine (HCQ) for COVID-19: more than 1100 deaths question ethics and safety overall

• SIMPLE study reports benefit from 5-day but not 10-day remdesivir on moderate COVID-19

• Recent papers on convalescent plasma and on ACE inhibitors and angiotensin receptor blockers

COVID-19: guidelines

• BHIVA/THT updated guidelines for social distancing in the UK

COVID-19: transmission & prevention

• Two PEP studies report no benefit of hydroxychloroquine for preventing CoV-2 infection

COVID-19: on the web

• Independent SAGE: UK COVID-19 policy responses

• COVID-19 harm reduction programmes in Central and Eastern Europe and Central Asia

PDFs

• HIV and COVID-19 bulletin no 5 (26 June 2020)